XTLB
XTL Biopharmaceuticals Ltd.
Price Chart
Latest Quote
$2.83
-0.10 (-3.41%)
Current Price
| Previous Close | $2.93 |
| Open | $2.83 |
| Day High | $2.83 |
| Day Low | $2.83 |
| Volume | 467 |
Stock Information
| Shares Outstanding | 2.46M |
| Cash Equivalents | $76K |
| Net Income | $-759K |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $6.98M |
| EPS (TTM) | $-0.37 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $6.90M |
| Income | $-759K |
| Cash/sh | $0.03 |
| Employees | 4 |
Financial Ratios
| Quick Ratio | 0.18 |
| Current Ratio | 0.40 |
Returns & Margins
| ROA | -21.01% |
| ROE | -29.30% |
Ownership
| Insider Ownership | 38.46% |
| Institutional Ownership | 3.08% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| PEG | 2.27 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $2.76 |
| SMA50 | $2.59 |
| SMA200 | $3.26 |
| RSI | 63.48 |
| ATR | 0.3293 |
| Shares Float | 829K |
| Short Float | 0.51% |
| Short Ratio | 0.05 |
| Volatility | 0.55 |
| Rel Volume | 0.01 |
Performance History
| Week | -2.41% |
| Month | +19.33% |
| Quarter | +14.52% |
| 6 Months | -24.47% |
| YTD | +18.33% |
| Year | -52.98% |
| 3 Years | -26.80% |
| 5 Years | -80.65% |
| 10 Years | -86.97% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $2.84 | 2,400 |
| 2026-07-16 | $2.83 | 2,400 |
| 2026-07-15 | $2.93 | 1,700 |
| 2026-07-14 | $2.96 | 44,600 |
| 2026-07-13 | $2.88 | 5,600 |
| 2026-07-10 | $2.91 | 15,800 |
| 2026-07-09 | $2.89 | 5,400 |
| 2026-07-08 | $2.90 | 14,300 |
| 2026-07-07 | $2.98 | 26,900 |
| 2026-07-06 | $3.14 | 150,600 |
| 2026-07-02 | $2.70 | 45,900 |
| 2026-07-01 | $2.49 | 297,700 |
| 2026-06-30 | $2.73 | 3,232,700 |
| 2026-06-29 | $2.36 | 100,600 |
| 2026-06-26 | $2.36 | 35,200 |
| 2026-06-25 | $2.57 | 22,800 |
| 2026-06-24 | $2.79 | 5,800 |
| 2026-06-23 | $2.79 | 21,600 |
| 2026-06-22 | $2.70 | 26,400 |
| 2026-06-18 | $2.54 | 10,700 |
About XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.
đ° Latest News
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $0 | $0 | $0 | $0 |
| Cost Of Revenue | $0 | $0 | $0 | $0 |
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $7,000 | $28,000 | $0 | $0 |
| Total Expenses | $1,380,000 | $775,000 | $765,000 | $880,000 |
| Rent Expense Supplemental | $0 | $0 | $12,000 | $6,000 |
| Other Income Expense | $647,000 | $1,067,000 | $-1,054,000 | $-493,000 |
| Net Non Operating Interest Income Expense | $-26,000 | $-52,000 | $37,000 | $25,000 |
| Total Other Finance Cost | $79,000 | $58,000 | $4,000 | $11,000 |
| Interest Expense Non Operating | $7,000 | $28,000 | $0 | $0 |
| Operating Expense | $1,380,000 | $775,000 | $765,000 | $880,000 |
| Other Operating Expenses | $223,000 | - | - | - |
| General And Administrative Expense | $1,129,000 | $759,000 | $734,000 | $850,000 |
| Selling And Marketing Expense | - | $178,000 | $0 | $0 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-759,000 | $240,000 | $-1,782,000 | $-1,348,000 |
| Net Interest Income | $-26,000 | $-52,000 | $37,000 | $25,000 |
| Interest Income | $60,000 | $34,000 | $41,000 | $36,000 |
| Normalized Income | $-1,406,000 | $-827,000 | $-728,000 | $-855,000 |
| Net Income From Continuing And Discontinued Operation | $-6,969,000 | $-1,027,000 | $-1,782,000 | $-1,348,000 |
| Total Operating Income As Reported | $-1,688,000 | $-775,000 | $-765,000 | $-880,000 |
| Net Income Common Stockholders | $-6,969,000 | $-1,027,000 | $-1,782,000 | $-1,348,000 |
| Net Income | $-6,969,000 | $-1,027,000 | $-1,782,000 | $-1,348,000 |
| Net Income Including Noncontrolling Interests | $-6,969,000 | $-1,027,000 | $-1,782,000 | $-1,348,000 |
| Net Income Discontinuous Operations | $-6,210,000 | $-1,267,000 | $0 | - |
| Net Income Continuous Operations | $-759,000 | $240,000 | $-1,782,000 | $-1,348,000 |
| Pretax Income | $-759,000 | $240,000 | $-1,782,000 | $-1,348,000 |
| Special Income Charges | $-308,000 | $0 | $0 | - |
| Interest Income Non Operating | $60,000 | $34,000 | $41,000 | $36,000 |
| Operating Income | $-1,380,000 | $-775,000 | $-765,000 | $-880,000 |
| Gross Profit | $0 | $0 | $0 | $0 |
| Depreciation Amortization Depletion Income Statement | - | $31,000 | $0 | $0 |
| Depreciation And Amortization In Income Statement | - | $31,000 | $0 | $0 |
| Amortization Of Intangibles Income Statement | - | $31,000 | $0 | $0 |
| Average Dilution Earnings | - | - | $0 | $0 |
| Per Share | ||||
| Diluted EPS | - | $-0.80 | $-1.20 | $-0.80 |
| Basic EPS | - | $-0.80 | $-1.20 | $-0.80 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-1,399,000 | $-600,000 | $-728,000 | $-854,000 |
| Total Unusual Items | $647,000 | $1,067,000 | $-1,054,000 | $-493,000 |
| Total Unusual Items Excluding Goodwill | $647,000 | $1,067,000 | $-1,054,000 | $-493,000 |
| Reconciled Depreciation | $0 | $199,000 | $0 | $1,000 |
| EBITDA (Bullshit earnings) | $-752,000 | $467,000 | $-1,782,000 | $-1,347,000 |
| EBIT | $-752,000 | $268,000 | $-1,782,000 | $-1,348,000 |
| Diluted NI Availto Com Stockholders | $-6,969,000 | $-1,027,000 | $-1,782,000 | $-1,348,000 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Write Off | $308,000 | $0 | $0 | - |
| Gain On Sale Of Security | $955,000 | $1,067,000 | $-1,054,000 | $-493,000 |
| Research And Development | $28,000 | $16,000 | $31,000 | $30,000 |
| Selling General And Administration | $1,129,000 | $759,000 | $734,000 | $850,000 |
| Other Gand A | $361,000 | $213,000 | $433,000 | $443,000 |
| Insurance And Claims | $107,000 | $100,000 | $119,000 | $202,000 |
| Rent And Landing Fees | $0 | $0 | $12,000 | $6,000 |
| Salaries And Wages | $661,000 | $446,000 | $170,000 | $199,000 |
| Diluted Average Shares | - | $1,682,612 | $1,362,265 | $1,362,273 |
| Basic Average Shares | - | $1,682,612 | $1,362,265 | $1,362,265 |
| Amortization | - | $31,000 | $0 | $0 |
Fetched: 2026-07-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-254,000 | $-1,574,000 | $1,840,000 | $3,619,000 |
| Total Assets | $166,000 | $8,550,000 | $2,426,000 | $4,186,000 |
| Total Non Current Assets | $0 | $7,210,000 | $380,000 | $380,000 |
| Investmentin Financial Assets | $0 | $14,000 | $0 | - |
| Goodwill And Other Intangible Assets | $0 | $7,009,000 | $380,000 | $380,000 |
| Current Assets | $166,000 | $1,340,000 | $2,046,000 | $3,806,000 |
| Other Current Assets | $22,000 | $47,000 | $11,000 | $14,000 |
| Receivables | $0 | $150,000 | $0 | $71,000 |
| Accounts Receivable | $0 | $99,000 | $0 | - |
| Allowance For Doubtful Accounts Receivable | $0 | $-36,000 | $0 | - |
| Gross Accounts Receivable | $0 | $135,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $144,000 | $1,143,000 | $2,006,000 | $3,721,000 |
| Cash And Cash Equivalents | $76,000 | $371,000 | $1,401,000 | $2,094,000 |
| Cash Financial | $76,000 | $371,000 | $133,000 | $1,413,000 |
| Other Intangible Assets | - | $3,816,000 | $380,000 | $380,000 |
| Prepaid Assets | - | $51,000 | $29,000 | $71,000 |
| Other Receivables | - | $51,000 | $29,000 | $71,000 |
| Cash Equivalents | - | $0 | $1,268,000 | $681,000 |
| Debt | ||||
| Net Debt | $193,000 | - | - | - |
| Total Debt | $269,000 | $138,000 | - | - |
| Current Debt And Capital Lease Obligation | $269,000 | $138,000 | - | - |
| Current Debt | $269,000 | $138,000 | - | - |
| Other Current Borrowings | $269,000 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $420,000 | $3,115,000 | $206,000 | $187,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $908,000 | $0 | $0 |
| Derivative Product Liabilities | $0 | $689,000 | $0 | $0 |
| Non Current Deferred Liabilities | $0 | $219,000 | $0 | - |
| Non Current Deferred Taxes Liabilities | $0 | $219,000 | $0 | - |
| Current Liabilities | $420,000 | $2,207,000 | $206,000 | $187,000 |
| Current Deferred Liabilities | $0 | $18,000 | $0 | - |
| Payables And Accrued Expenses | $149,000 | $719,000 | $206,000 | $187,000 |
| Payables | $20,000 | $227,000 | $1,000 | $2,000 |
| Accounts Payable | $20,000 | $196,000 | $1,000 | $2,000 |
| Other Current Liabilities | - | $1,279,000 | - | - |
| Other Payable | - | $31,000 | - | - |
| Equity | ||||
| Common Stock Equity | $-254,000 | $5,435,000 | $2,220,000 | $3,999,000 |
| Total Equity Gross Minority Interest | $-254,000 | $5,435,000 | $2,220,000 | $3,999,000 |
| Stockholders Equity | $-254,000 | $5,435,000 | $2,220,000 | $3,999,000 |
| Gains Losses Not Affecting Retained Earnings | $20,000 | $20,000 | $20,000 | $20,000 |
| Other Equity Adjustments | $20,000 | $20,000 | $20,000 | $20,000 |
| Retained Earnings | $-165,632,000 | $-159,009,000 | $-158,246,000 | $-156,467,000 |
| Other | ||||
| Treasury Shares Number | $372,957,973 | - | - | - |
| Ordinary Shares Number | $946,243,356 | $881,385,176 | $544,906,149 | $544,906,149 |
| Share Issued | $1,319,201,329 | $881,385,176 | $544,906,149 | $544,906,149 |
| Tangible Book Value | $-254,000 | $-1,574,000 | $1,840,000 | $3,619,000 |
| Invested Capital | $15,000 | $5,573,000 | $2,220,000 | $3,999,000 |
| Working Capital | $-254,000 | $-867,000 | $1,840,000 | $3,619,000 |
| Total Capitalization | $-254,000 | $5,435,000 | $2,220,000 | $3,999,000 |
| Additional Paid In Capital | $140,219,000 | $141,286,000 | $146,326,000 | $146,326,000 |
| Capital Stock | $25,139,000 | $23,138,000 | $14,120,000 | $14,120,000 |
| Common Stock | $25,139,000 | $23,138,000 | $14,120,000 | $14,120,000 |
| Current Deferred Revenue | $0 | $18,000 | $0 | - |
| Line Of Credit | $0 | $138,000 | $0 | - |
| Pensionand Other Post Retirement Benefit Plans Current | $2,000 | $53,000 | $0 | - |
| Current Accrued Expenses | $129,000 | $492,000 | $205,000 | $185,000 |
| Investments And Advances | $0 | $14,000 | $0 | - |
| Goodwill | $0 | $3,193,000 | $0 | - |
| Net PPE | $0 | $187,000 | $0 | $0 |
| Other Short Term Investments | $68,000 | $772,000 | $605,000 | $1,627,000 |
| Available For Sale Securities | - | $14,000 | - | - |
Fetched: 2026-07-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-1,025,000 | $-1,672,000 | $-707,000 | $-901,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-1,025,000 | $-1,618,000 | $-707,000 | $-901,000 |
| Cash Flow From Continuing Operating Activities | $-1,025,000 | $-1,618,000 | $-707,000 | $-901,000 |
| Operating Gains Losses | $5,108,000 | $-926,000 | $27,000 | $-1,054,000 |
| Investing Activities | ||||
| Investing Cash Flow | $522,000 | $-844,000 | $41,000 | $36,000 |
| Cash Flow From Continuing Investing Activities | $522,000 | $-844,000 | $41,000 | $36,000 |
| Net Other Investing Changes | $-250,000 | $-400,000 | - | - |
| Capital Expenditure | - | $-54,000 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $1,460,000 | $0 | $0 |
| Financing Cash Flow | $208,000 | $1,447,000 | $0 | $0 |
| Cash Flow From Continuing Financing Activities | $208,000 | $1,447,000 | $0 | $0 |
| Net Common Stock Issuance | $0 | $1,460,000 | $0 | $0 |
| Common Stock Issuance | $0 | $1,460,000 | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $0 | $-13,000 | $0 | $0 |
| Issuance Of Debt | $208,000 | $0 | $0 | - |
| End Cash Position | $76,000 | $371,000 | $1,401,000 | $2,094,000 |
| Beginning Cash Position | $371,000 | $1,401,000 | $2,094,000 | $2,969,000 |
| Effect Of Exchange Rate Changes | $0 | $-15,000 | $-27,000 | $-10,000 |
| Changes In Cash | $-295,000 | $-1,015,000 | $-666,000 | $-865,000 |
| Net Issuance Payments Of Debt | $208,000 | $-13,000 | $0 | $0 |
| Net Short Term Debt Issuance | $0 | $-13,000 | $0 | $0 |
| Short Term Debt Payments | $0 | $-13,000 | $0 | $0 |
| Net Long Term Debt Issuance | $208,000 | $0 | $0 | - |
| Long Term Debt Issuance | $208,000 | $0 | $0 | - |
| Interest Received Cfi | $0 | $34,000 | $41,000 | $36,000 |
| Net Investment Purchase And Sale | $777,000 | $-14,000 | $0 | $0 |
| Sale Of Investment | $777,000 | $0 | $0 | - |
| Purchase Of Investment | $0 | $-14,000 | $0 | $0 |
| Net Business Purchase And Sale | $-5,000 | $-410,000 | $0 | $0 |
| Purchase Of Business | $-5,000 | $-410,000 | $0 | $0 |
| Net PPE Purchase And Sale | $0 | $-54,000 | $0 | $0 |
| Purchase Of PPE | $0 | $-54,000 | $0 | $0 |
| Change In Working Capital | $-2,000 | $189,000 | $64,000 | $-19,000 |
| Change In Payables And Accrued Expense | $-187,000 | $208,000 | $19,000 | $-44,000 |
| Change In Payable | $-187,000 | $208,000 | $19,000 | $-44,000 |
| Change In Account Payable | $-187,000 | $208,000 | $19,000 | $-44,000 |
| Change In Prepaid Assets | $28,000 | $-58,000 | $45,000 | $25,000 |
| Change In Receivables | $157,000 | $39,000 | $0 | $0 |
| Changes In Account Receivables | $157,000 | $39,000 | $0 | $0 |
| Other Non Cash Items | $-34,000 | $-20,000 | $-14,000 | $-26,000 |
| Stock Based Compensation | $346,000 | $264,000 | $3,000 | $14,000 |
| Unrealized Gain Loss On Investment Securities | $-5,000 | $-167,000 | $1,022,000 | $1,531,000 |
| Asset Impairment Charge | $531,000 | $0 | $0 | - |
| Deferred Tax | $0 | $-130,000 | $0 | $0 |
| Deferred Income Tax | $0 | $-130,000 | $0 | $0 |
| Depreciation Amortization Depletion | $0 | $199,000 | $0 | $1,000 |
| Depreciation And Amortization | $0 | $199,000 | $0 | $1,000 |
| Gain Loss On Investment Securities | $-1,102,000 | $-926,000 | - | $-1,054,000 |
| Gain Loss On Sale Of Business | $6,210,000 | $0 | $0 | - |
| Net Income From Continuing Operations | $-6,969,000 | $-1,027,000 | $-1,782,000 | $-1,348,000 |
| Proceeds From Stock Option Exercised | - | - | $0 | $0 |
| Sale Of Business | - | - | $0 | - |
| Depreciation | - | - | $0 | $1,000 |
| Net Foreign Currency Exchange Gain Loss | - | - | $27,000 | $10,000 |
Fetched: 2026-07-16